Companies
/
PathAI
Healthtech
PathAI is a Boston-based healthcare technology company using AI to analyze pathology images, providing AI-assisted pathology analysis and decision-support tools supporting pharmaceutical research.
Create an account to view live offerings, pricing, and market activity.
Sign in to view offerings and live market activity.
PathAI was founded in 2016 by Andy Beck and Aditya Khosla, based on research applying machine learning and computer vision to pathology, the medical specialty involving diagnosing disease by examining tissue samples under a microscope, a discipline that has historically relied entirely on a human pathologist's visual interpretation of tissue slides, a process that, despite pathologists' extensive training, is subject to some degree of interobserver variability, meaning different pathologists examining the same tissue sample can sometimes reach somewhat different diagnostic conclusions or severity assessments, particularly for more subtle or ambiguous cases. PathAI's platform uses machine learning models trained on large volumes of digitized pathology images, paired with known diagnostic outcomes, to help pathologists more consistently and accurately identify and characterize disease patterns in tissue samples, functioning as a decision-support tool that can flag areas of a tissue sample warranting closer attention, quantify certain disease characteristics more precisely and consistently than purely visual human assessment alone, such as counting specific cell types or measuring the extent of disease involvement within a tissue sample, and help reduce the diagnostic variability that can occur when different pathologists interpret the same case somewhat differently. The company has focused significant efforts on oncology applications, where precise, consistent pathology assessment is particularly important both for individual patient treatment decisions and for pharmaceutical companies conducting cancer drug clinical trials, where consistent, quantifiable pathology assessment criteria across many different clinical trial sites and pathologists is important for reliable trial results. PathAI has built partnerships with pharmaceutical companies to support drug development research, using its AI-driven pathology analysis to help identify patient populations likely to respond to a given cancer treatment and to support the pathology components of clinical trials evaluating new cancer therapies. The company's customers span pharmaceutical companies conducting drug development research and clinical laboratories seeking AI-assisted diagnostic support tools. PathAI has raised substantial venture funding from investors including General Catalyst, General Atlantic, and Tiger Global, reaching a valuation exceeding $1.5 billion.
FOR QUALIFIED INSTITUTIONAL AND ACCREDITED INVESTORS ONLY: Under federal securities laws, private market investments on this platform are available exclusively to Institutional and Accredited Investors. Verification of status required before investing. Private investments involve significant risks including illiquidity, potential loss of principal, and limited disclosure requirements. "Augment" refers to Augment Markets, Inc. and its affiliates. Augment Markets, Inc. is a technology company offering software and data services, not a bank or financial institution. Cash Accounts are provided by Modern Treasury Corp. financial institution partners and through Augment's technology. Augment does not act as a money services business, provide money transmission, or serve as a custodian of funds. Funds held in your Cash Account are not FDIC insured unless expressly disclosed. Full terms available in the Augment Cash Account Agreement. Brokerage services are offered through Augment Capital, LLC, an affiliated broker-dealer and member FINRA/SIPC. "Investment accounts" are not brokerage accounts and do not hold customer funds or securities. Investment advisory services are offered through Augment Advisors, LLC, an SEC-registered investment adviser. Registration with the SEC does not imply a certain level of skill or training. Neither Augment Advisors, LLC nor Augment Capital, LLC provide legal or tax advice; consult your attorney or tax professional regarding your specific situation. For additional information, please refer to Augment Advisors, LLC's Form ADV Part 2A (Firm Brochure) and FINRA BrokerCheck.
